Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR101 Oral Immunotherapy for Peanut Allergy (ARC002)
NCT02198664Phase 2Completed
- Start
- Aug 2014
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, open-label trial of peanut oral immunotherapy in peanut allergy (2 arms). Primary endpoint: Adverse Events at 90 weeks. Started Aug 2014; status: completed.
02
Drugs
peanut oral immunotherapy
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT02198664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198664.